CordenPharma, a Swiss CDMO specialised in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products has entered into a collaboration with Viking Therapeutics, a clinical-stage company focused on developing novel therapies for metabolic and endocrine disorders.

As part of the multi-year supply contract, CordenPharma will provide development and manufacturing services for Viking Therapeutics’ GLP-1 drug candidate VK2735, which is a Dual GLP-1/GIP Receptor Agonist. This will involve the full supply chain of the drug, from substance to product and for both subcutaneous and oral peptide formulations. To ensure a smooth transition of the development and commercialisation of Viking Therapeutics’ VK2735 drug candidate, CordenPharma will utilise its global network of manufacturing facilities for drug substance, fill-finish and oral solid dosage finished product; this serves to secure an uninterrupted supply chain throughout the stages of Viking Therapeutics’ VK2735 drug candidate process.